BIOLEGEND TAIWAN INC.
Update：2023/06/12
Industries
Main Industry
Biotechnology
Main Product/Service
1. Antibodies and Reagents
2. Apoptosis and Cell Health Reagents
3. Buffers and Chemical Probes
4. Clinical | Analyte Specific Reagents (ASR)
5. Isotype Controls
6. Magnetic Separation - MojoSort?
7. Non-Human Primate Antibodies
8. Recombinant Proteins, Cytokines, Growth Factors
9. SARS-CoV-2 Reagents
10. Soluble MHC ? Flex?T?
11. Ultra-LEAF? | GoInVivo? Antibodies
12. Cell-Vive? GMP Portfolio
2. Apoptosis and Cell Health Reagents
3. Buffers and Chemical Probes
4. Clinical | Analyte Specific Reagents (ASR)
5. Isotype Controls
6. Magnetic Separation - MojoSort?
7. Non-Human Primate Antibodies
8. Recombinant Proteins, Cytokines, Growth Factors
9. SARS-CoV-2 Reagents
10. Soluble MHC ? Flex?T?
11. Ultra-LEAF? | GoInVivo? Antibodies
12. Cell-Vive? GMP Portfolio
Founded Year
2010
Unified Business No.
53138320
Status
Active
Number of Employees
0
Total Paid-in
Capital
100,000,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Website
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure.
Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
